PMID- 37334144
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230620
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 16
DP  - 2023
TI  - Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs 
      and Half-Dose CAG for Unfit or Refractory/Relapsed AML.
PG  - 409-419
LID - 10.2147/OTT.S405611 [doi]
AB  - PURPOSE: The prognosis of patients with unfit or relapsed/refractory (R/R) AML 
      remains poor. Venetoclax (VEN) has been shown to exhibit anti-leukemia stem cell 
      activity; however, few studies have been published on the efficacy and safety of 
      VEN combined with both hypomethylating agents (HMAs) and low-dose chemotherapy 
      for patients with unfit or R/R AML. METHODS: This study retrospectively analyzed 
      the clinical characteristics, treatment details, safety profile and clinical 
      outcomes of patients with unfit or R/R AML treated with VEN+ HMAs+ half-dose CAG 
      (LDAC, aclarubicin and granulocyte colony-stimulating factor). RESULTS: A total 
      of 24 AML patients were involved in the study, of whom 13 (54.2%) were in the 
      unfit group, and 11 (45.8%) were in the R/R group. FLT3 and IDH (8/24, 33.3%) 
      were the most common gene aberrations. Patients in the R/R group were found to be 
      more likely to carry KIT (5/11, 45.5%) compared with the unfit group (0/13, 0%) 
      (P = 0.006). The ORR observed during the study was 83.3% (20/24; 14 CR, 2CRi, 
      4PR). In the unfit group, 11/13 (84.6%) patients achieved cCR (10 CR and 1 CRi); 
      while 5/11 (45.5%) R/R patients achieved response (4 CR and 1 CRi). CR was 
      observed in all AML patients with TP53 (5/5), GATA2 (3/3), CEBPA (3/3) and ASXL1 
      (3/3). The most common adverse events (AEs) during VEN+ HMAs+ half-dose CAG 
      therapy were persistent cytopenias and infections. CONCLUSION: The results of 
      this study confirm that VEN+ HMAs+ half-dose CAG is associated with promising 
      efficacy (even high-risk molecular patterns) and tolerable safety profile in 
      patients with unfit or R/R AML. Yet, the study involves only a small sample size, 
      which should not be overlooked. As such, further studies on the efficacy of VEN 
      combined with HMAs and half-dose CAG regimen in AML patients are essential.
CI  - (c) 2023 Chen et al.
FAU - Chen, Xiaotong
AU  - Chen X
AD  - Department of Hematology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, 150001, People's Republic of China.
FAU - Zhao, Yanqiu
AU  - Zhao Y
AD  - Department of Hematology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, 150001, People's Republic of China.
FAU - Li, Qi
AU  - Li Q
AD  - Department of Hematology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, 150001, People's Republic of China.
FAU - Fan, Shengjin
AU  - Fan S
AD  - Department of Hematology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, 150001, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20230613
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC10276600
OTO - NOTNLM
OT  - BCL2 inhibitor
OT  - acute myeloid leukemia
OT  - combined chemotherapy
OT  - venetoclax
COIS- There is no competing interest among the authors.
EDAT- 2023/06/19 06:41
MHDA- 2023/06/19 06:42
PMCR- 2023/06/13
CRDT- 2023/06/19 03:01
PHST- 2023/02/03 00:00 [received]
PHST- 2023/05/18 00:00 [accepted]
PHST- 2023/06/19 06:42 [medline]
PHST- 2023/06/19 06:41 [pubmed]
PHST- 2023/06/19 03:01 [entrez]
PHST- 2023/06/13 00:00 [pmc-release]
AID - 405611 [pii]
AID - 10.2147/OTT.S405611 [doi]
PST - epublish
SO  - Onco Targets Ther. 2023 Jun 13;16:409-419. doi: 10.2147/OTT.S405611. eCollection 
      2023.